论文部分内容阅读
目的：研究脂肪乳剂在治疗慢性重症肝炎时对肝功能和疾病预后的影响。方法：同期收治44例慢性重症肝炎患者随机分成两组，在均实行综合治疗基础上，治疗组使用20％脂肪乳剂，对照组则不用。观察治疗前后其血清甘油三脂（TG）、胆红素（SB）、谷丙转氨酶（ALT）、凝血酶原活动度（PFA）和治疗后病死率。结果：治疗前两组间TG、SB、ALT及PTA均无显著差异（P＞0．05）。治疗结束后，治疗组TC平均升高1．10mmol／L，对照组平均升高0．44mmol／L（P＜0．01）；治疗组SB及ALT分别平均降低126umol／L和549u／L，对照组则分别平均降低66umol／L和498u／L，两组差异显著（P＜0．05）；治疗组PTA平均升高25个百分点，对照组PTA平均升高对个百分点（P＞0．05）；两组病死率无显著差异（P＞0．05）。结论脂肪乳剂作为重症肝炎治疗中辅助措施，可增加血脂水平、促进血清胆红素及谷丙转氨酶下降。
Objective: To study the effect of fat emulsion on the prognosis of liver function and disease in the treatment of chronic severe hepatitis. Methods: Forty-four patients with chronic severe hepatitis treated in the same period were randomly divided into two groups. On the basis of comprehensive treatment, 20% fat emulsion was used in the treatment group and no in the control group. Serum triglyceride (TG), bilirubin (SB), alanine aminotransferase (ALT), prothrombin activity (PFA) and post-treatment mortality were observed before and after treatment. Results: There was no significant difference in TG, SB, ALT and PTA between the two groups before treatment (P> 0.05). After treatment, TC in treatment group increased by 1.10mmol / L on average and in control group increased by 0.44mmol / L (P <0.01), SB and ALT decreased by 126umol / L and 549u / L on average, (P <0.05). The average PTA in the treatment group was increased by 25% and that in the control group was increased by an average of 60%. There was no significant difference between the two groups (P> 0.05). Conclusion As a supplementary measure in the treatment of severe hepatitis, lipid emulsion can increase the level of blood lipid and promote the decrease of serum bilirubin and alanine aminotransferase.